Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
- Associated Therapies
- -
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002515
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00008008
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States
🇺🇸Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-12-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT00002718
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- New Approaches to Brain Tumor Therapy Consortium
- Registration Number
- NCT00045539
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 361
- Registration Number
- NCT00003816
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-08-04
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 72
- Registration Number
- NCT00004092
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 50
- Registration Number
- NCT00025077
- Locations
- 🇬🇧
Great Ormond Street Hospital for Children NHS Trust, London, England, United Kingdom
🇬🇧Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
🇬🇧Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00003199
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/Puget Sound Oncology Consortium, Seattle, Washington, United States
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-03-28
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00025558
- Locations
- 🇦🇺
Princess Margaret Hospital for Children, Perth, Western Australia, Australia
🇺🇸NYU Cancer Institute at New York University Medical Center, New York, New York, United States
🇺🇸Columbus Children's Hospital, Columbus, Ohio, United States
Multiple Therapies in Treating Patients With Advanced Neuroblastoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00040872
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.